Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 5/20 | 1.00 |
| ▸ | RPS6KA3 | P51812 | 4/20 | 1.00 |
| ▸ | IRAK4 | Q9NWZ3 | 3/20 | 1.00 |
| ▸ | AURKB | Q96GD4 | 18/20 | 0.98 |
| ▸ | FLT3 | P36888 | 3/20 | 0.98 |
| ▸ | EPHB4 | P54760 | 3/20 | 0.98 |
| ▸ | LCK | P06239 | 3/20 | 0.65 |
| ▸ | KDR | P35968 | 1/20 | 0.63 |
| ▸ | PTK6 | Q13882 | 1/20 | 0.63 |
| ▸ | AURKA | O14965 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13153248 | 0.94 | CHEK1 (0.89) | CHEK1RPS6KA3IRAK4AURKBFLT3 | |
| SCHEMBL12588180 | 0.94 | CHEK1 (0.88) | CHEK1RPS6KA3IRAK4AURKBFLT3 | |
| SCHEMBL13155484 | 0.92 | CHEK1 (0.85) | CHEK1RPS6KA3IRAK4AURKBFLT3 | |
| SCHEMBL13617843 | 0.92 | AURKB (1.00) | CHEK1RPS6KA3IRAK4AURKBFLT3 | |
| SCHEMBL13983735 | 0.90 | CHEK1 (0.82) | CHEK1RPS6KA3IRAK4AURKBFLT3 | |
| SCHEMBL12588184 | 0.88 | CHEK1 (0.78) | CHEK1RPS6KA3IRAK4AURKBFLT3 | |
| SCHEMBL12588157 | 0.87 | AURKB (0.89) | CHEK1RPS6KA3IRAK4AURKBFLT3 | |
| SCHEMBL12588199 | 0.86 | AURKB (0.88) | CHEK1RPS6KA3IRAK4AURKBFLT3 | |
| SCHEMBL13155431 | 0.86 | AURKB (0.79) | CHEK1RPS6KA3IRAK4AURKBFLT3 | |
| SCHEMBL13155483 | 0.86 | CHEK1 (0.75) | CHEK1RPS6KA3IRAK4AURKBFLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116334024-A | Aurora kinase B gene K85 and K87 mutation and application thereof | 北京大学 | 2023-06-27 | — | — | CN | claimed |
| CN-116004567-A | Aurora kinase B gene K202 mutation and application thereof | 北京大学 | 2023-04-25 | — | — | CN | claimed |
| US-12637720-B2 | Molecular subtyping of small cell lung cancer to predict therapeutic responses | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2026-05-26 | — | — | US | disclosed |
| WO-2026107052-A1 | COMBINATION TREATMENTS USING EPIGENETIC INHIBITION AND SYNGRI-MEDIATED FRATAXIN EXPRESSION | ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC. (US) | 2026-05-21 | — | — | WO | disclosed |
| EP-4115907-B1 | COMBINATION DRUG OF KINASE INHIBITORS FOR USE IN THE TREATMENT OF PANCREATIC CANCER | UNIV HOKKAIDO NAT UNIV CORP (JP) | 2026-05-06 | — | — | EP | disclosed |
| US-20250161287-A1 | METHODS, COMPOSITIONS, AND COMBINATIONS FOR PREVENTING OR TREATING CANCER RECURRENCE | VUJA DE SCIENCES INC (US) | 2025-05-22 | — | — | US | disclosed |
| US-12295955-B2 | TTP phosphorylation for the identification of personalized medicines | KING FAISAL SPECIALIST HOSPITAL & RESEARCH CENTRE (SA) | 2025-05-13 | — | — | US | disclosed |
| US-20240390406-A1 | PHOSPHORYLATED TRISTETRAPROLIN AS A BIOMARKER AND THERAPEUTIC TARGET FOR ANTIAGING DRUGS | KING FAISAL SPECIALIST HOSPITAL & RESEARCH CENTRE (SA) | 2024-11-28 | — | — | US | disclosed |
| EP-4467978-A1 | PHOSPHORYLATED TRISTETRAPROLIN AS A BIOMARKER AND THERAPEUTIC TARGET FOR ANTI-AGING DRUGS | King Faisal Specialist Hospital & Research Centre (SA) | 2024-11-27 | — | — | EP | disclosed |
| CN-114207437-B | Method for screening anticancer agent and combination drug of kinase inhibitor for treating pancreatic cancer | 国立大学法人北海道大学 | 2024-05-28 | — | — | CN | disclosed |
| US-20240150848-A1 | METHODS AND SYSTEMS FOR DIAGNOSIS, CLASSIFICATION, AND TREATMENT OF SMALL CELL LUNG CANCER AND OTHER HIGH-GRADE NEUROENDOCRINE CARCINOMAS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-05-09 | — | — | US | disclosed |
| US-20220387630-A1 | METHOD FOR SCREENING ANTICANCER AGENT AND COMBINATION DRUG OF KINASE INHIBITORS FOR TREATMENT OF PANCREATIC CANCER | NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (JP) | 2022-12-08 | — | — | US | disclosed |
| WO-2022187554-A1 | METHODS AND SYSTEMS FOR DIAGNOSIS, CLASSIFICATION, AND TREATMENT OF SMALL CELL LUNG CANCER AND OTHER HIGH-GRADE NEUROENDOCRINE CARCINOMAS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-09-09 | — | — | WO | disclosed |
| WO-2022098979-A1 | METHODS AND SYSTEMS FOR CLASSIFICATION AND TREATMENT OF SMALL CELL LUNG CANCER | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-05-12 | — | — | WO | disclosed |
| CN-114207437-A | Method of screening anticancer agent and combination drug of kinase inhibitor for treating pancreatic cancer | 国立大学法人北海道大学 | 2022-03-18 | — | — | CN | disclosed |
| WO-2010124009-A2 | FULLY HUMAN ANTI-VEGF ANTIBODIES AND METHODS OF USING | SCHERING CORPORATION (US) | 2010-10-28 | — | — | WO | disclosed |
| US-20100249030-A1 | ANTI-MITOTIC AGENT AND AURORA KINASE INHIBITOR COMBINATION AS ANTI-CANCER TREATMENT | SCHERING CORPORATION | 2010-09-30 | — | — | US | disclosed |
| US-20100249030-A1 | ANTI-MITOTIC AGENT AND AURORA KINASE INHIBITOR COMBINATION AS ANTI-CANCER TREATMENT | SCHERING CORPORATION | 2010-09-30 | — | — | US | disclosed |
| WO-2009017701-A2 | ANTI-MITOTIC AGENT AND AURORA KINASE INHIBITOR COMBINATION AS ANTI-CANCER TREATMENT | SCHERING CORPORATION (US) | 2009-02-05 | — | — | WO | disclosed |
| WO-2008156614-A2 | IMIDAZOPYRAZINES AS PROTEIN KINASE INHIBITORS | SCHERING CORPORATION (US) | 2008-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249030-A1 | ANTI-MITOTIC AGENT AND AURORA KINASE INHIBITOR COMBINATION AS ANTI-CANCER TREATMENT | AURKC, AURKA, AURKB | CHEK1 61/4885RPS6KA3 1157/4885IRAK4 2539/4885 |
| US-12637720-B2 | Molecular subtyping of small cell lung cancer to predict therapeutic responses | POU2F1, POU2F2, PARP2 | CHEK1 19/4885RPS6KA3 614/4885IRAK4 759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.